Related Experiment Video
Updated: Aug 15, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Nuclear receptor conformation, coregulators, and tamoxifen-resistant breast cancer
J D Graham1, D L Bain, J K Richer
1Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA. dinny.graham@uchsc.edu
Abstract:
The development of tamoxifen resistance and consequent disease progression are common occurrences in breast cancers, often despite the continuing expression of estrogen receptors (ER). Tamoxifen is a mixed antagonist, having both agonist and antagonist properties. We have suggested that the development of tamoxifen resistance is associated with an increase in its agonist-like properties, resulting in loss of antagonist effects or even inappropriate tumor stimulation. Nuclear receptor function is influenced by a family of transcriptional coregulators, that either enhance or suppress transcriptional activity. Using a mixed antagonist-biased two-hybrid screening strategy, we identified two such proteins: the human homolog of the nuclear receptor corepressor, N-CoR, and a novel coactivator, L7/SPA (Switch Protein for Antagonists). In transcriptional studies, N-CoR suppressed the agonist properties of tamoxifen and RU486, and L7/SPA increased agonist effects. We speculated that the relative levels of these coactivators and corepressors may determine the balance of agonist and antagonist properties of mixed antagonists, such as tamoxifen. Using quantitative RT-PCR, we, therefore, measured the levels of transcripts encoding these coregulators, as well as the corepressor SMRT, and the coactivator SRC-1, in a small cohort of tamoxifen-resistant and sensitive breast tumors. The results suggest that tumor sensitivity to mixed antagonists may be governed by a complex set of transcription factors, which we are only now beginning to understand.
Insights
Tamoxifen resistance in breast cancer may be linked to changes in nuclear receptor coregulators. Understanding these factors could reveal new therapeutic targets for overcoming resistance to endocrine therapy.
Area of Science:
- Endocrinology
- Molecular Biology
- Oncology
Background:
- Tamoxifen resistance is a major challenge in breast cancer treatment, even with continued estrogen receptor (ER) expression.
- Tamoxifen acts as a mixed antagonist, possessing both agonist and antagonist properties.
- Resistance may arise from tamoxifen exhibiting more agonist-like properties, potentially stimulating tumor growth.
Purpose of the Study:
- To investigate the role of nuclear receptor coregulators in tamoxifen resistance.
- To identify proteins influencing tamoxifen's agonist and antagonist activities.
- To explore the correlation between coregulator levels and tamoxifen sensitivity in breast tumors.
Main Methods:
- Utilized a mixed antagonist-biased two-hybrid screening to identify coregulators.
- Conducted transcriptional studies to assess the impact of N-CoR and L7/SPA on tamoxifen and RU486 activity.
- Employed quantitative RT-PCR to measure transcript levels of coregulators (N-CoR, SMRT, L7/SPA, SRC-1) in tumor samples.
Main Results:
- Identified N-CoR (nuclear receptor corepressor) and L7/SPA (coactivator) as key proteins influencing nuclear receptor activity.
- N-CoR suppressed agonist properties of tamoxifen and RU486, while L7/SPA enhanced them.
- Preliminary data suggest that relative levels of these coregulators may influence tamoxifen's agonist/antagonist balance.
Conclusions:
- The balance of agonist and antagonist properties of mixed antagonists like tamoxifen may be determined by coregulator expression levels.
- Tumor sensitivity to tamoxifen might be regulated by a complex interplay of transcription factors.
- Further research is needed to fully understand these transcription factors and their role in endocrine therapy resistance.
Related Concept Videos
Cooperative Binding of Transcription Regulators
Co-activators and Co-repressors
Regulation of Nuclear Protein Sorting
Cooperative Binding of Transcription Regulators
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

